> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Empagliflozin's cardiovascular benefit in Medicare data does not vary by social group
- URL: https://www.coios.me/empagliflozin-s-cardiovascular-benefit-in-medicare-data/
- Published: 2026-09-23T13:02:00.000Z
- Updated: 2026-09-23T21:35:26.000Z
- Description: In US Medicare claims for adults aged 65 and over with type 2 diabetes, empagliflozin initiation was associated with lower rates of major cardiovascular events, heart failure hospitalisation and all-cause mortality than DPP-4 inhibitors, with no difference by sociodemographic subgroup.
- Author: Daniel Ryan
- Tags: Healthcare today, Cardiovascular disease, Obesity, diabetes and the GLP-1 drugs, Inequalities in health and length of life, United States, #peer-reviewed, #confirms, #item, #source-2026-09

The EMPRISE analysis used 2014-2020 Medicare claims to compare propensity score-matched initiators of empagliflozin with those prescribed DPP-4 inhibitors or GLP-1 receptor agonists, all aged 65 and over with type 2 diabetes. Against DPP-4 inhibitors, empagliflozin carried hazard ratios of 0.77 for major cardiovascular events, 0.72 for heart failure hospitalisation and 0.66 for all-cause mortality; against GLP-1 receptor agonists the heart failure hazard ratio was 0.88\. The absolute benefit varied by baseline cardiovascular disease but not by age, sex, race, ethnicity or socioeconomic measures.

*Why it is interesting: Puts a trial-scale cardiovascular and mortality signal into routine claims data for people over 65, and reports where the absolute benefit concentrates.*

Source

[Diabetes Care, 21 September 2026](https://doi.org/10.2337/dca26-0039?ref=coios.me)

DOI

10.2337/dca26-0039

Type

Peer-reviewed article

Design

Propensity score-matched new-user cohort in US Medicare claims, 2014-2020, adults aged 65 and over with type 2 diabetes

Verdict

Confirms prior evidence

Driver

[Cardiovascular disease](https://www.coios.me/d-cardiovascular/)

Driver

[Obesity, diabetes and the GLP-1 drugs](https://www.coios.me/d-obesity-diabetes/)

Driver

[Inequalities in health and length of life](https://www.coios.me/d-health-inequality/)